TR201908822T4 - Yeni flavonoid bileşikleri ve bunların kullanımları. - Google Patents

Yeni flavonoid bileşikleri ve bunların kullanımları. Download PDF

Info

Publication number
TR201908822T4
TR201908822T4 TR2019/08822T TR201908822T TR201908822T4 TR 201908822 T4 TR201908822 T4 TR 201908822T4 TR 2019/08822 T TR2019/08822 T TR 2019/08822T TR 201908822 T TR201908822 T TR 201908822T TR 201908822 T4 TR201908822 T4 TR 201908822T4
Authority
TR
Turkey
Prior art keywords
flavonoid compounds
treatment
new flavonoid
compounds
new
Prior art date
Application number
TR2019/08822T
Other languages
English (en)
Turkish (tr)
Inventor
Andrew Mclachlan Grant
Original Assignee
Armaron Bio Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904444A external-priority patent/AU2012904444A0/en
Application filed by Armaron Bio Pty Ltd filed Critical Armaron Bio Pty Ltd
Publication of TR201908822T4 publication Critical patent/TR201908822T4/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06Benzopyran radicals
    • C07H17/065Benzo[b]pyrans
    • C07H17/07Benzo[b]pyran-4-ones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2019/08822T 2012-10-11 2013-10-11 Yeni flavonoid bileşikleri ve bunların kullanımları. TR201908822T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2012904444A AU2012904444A0 (en) 2012-10-11 Novel Flavonoid compounds and uses thereof

Publications (1)

Publication Number Publication Date
TR201908822T4 true TR201908822T4 (tr) 2019-07-22

Family

ID=50476785

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08822T TR201908822T4 (tr) 2012-10-11 2013-10-11 Yeni flavonoid bileşikleri ve bunların kullanımları.

Country Status (17)

Country Link
US (1) US10316053B2 (enExample)
EP (1) EP2906578B8 (enExample)
JP (2) JP6567419B2 (enExample)
KR (1) KR102169002B1 (enExample)
CN (2) CN107759553A (enExample)
AU (1) AU2013330222B2 (enExample)
BR (1) BR112015008156A2 (enExample)
CA (1) CA2887488C (enExample)
DK (1) DK2906578T3 (enExample)
ES (1) ES2730926T3 (enExample)
MX (1) MX368855B (enExample)
NZ (1) NZ707087A (enExample)
RU (1) RU2647842C2 (enExample)
SG (1) SG11201502758SA (enExample)
TR (1) TR201908822T4 (enExample)
WO (1) WO2014056038A1 (enExample)
ZA (1) ZA201502703B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111233806A (zh) * 2020-03-20 2020-06-05 武汉轻工大学 一种3,5,4'-三乙酰氧基-7-羟基黄酮的制备方法
CN112168976B (zh) * 2020-10-15 2022-11-04 天津科技大学 一种黄酮衍生物前药及合成和作为抗肿瘤药物的应用
CN115504970B (zh) * 2022-10-18 2023-04-18 黑龙江中医药大学 一种用于治疗心肌缺血的黄酮类衍生物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06161129A (ja) * 1992-11-25 1994-06-07 Mita Ind Co Ltd 電子写真感光体
EP1223928A2 (en) * 1999-07-08 2002-07-24 Patrick Thomas Prendergast Use of flavones, coumarins and related compounds to treat infections
WO2001021608A2 (en) * 1999-09-23 2001-03-29 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Novel flavonoids
JP2003019867A (ja) * 2001-04-19 2003-01-21 Mitsubishi Chemicals Corp 光記録媒体
GB0125532D0 (en) * 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
WO2006030322A2 (en) * 2004-09-17 2006-03-23 University Of Manitoba Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions
US20060084615A1 (en) * 2004-10-20 2006-04-20 Chan Albert S Puerarin derivatives and their medical uses
BRPI0608402B8 (pt) * 2005-03-11 2021-05-25 Armaron Bio Pty Ltd compostos de flavonóide e composições compreendendo os mesmos
JP2007230145A (ja) * 2006-03-02 2007-09-13 Mitsubishi Chemicals Corp 光学記録媒体の記録層形成用色素、及びそれを用いた光学記録媒体、その光学記録媒体の記録方法
WO2008011538A2 (en) 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
US7863323B1 (en) * 2006-10-27 2011-01-04 The University Of Melbourne Flavonols
DE102008012909A1 (de) 2008-03-06 2009-09-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen
CN101244057B (zh) * 2008-03-11 2010-06-02 中国人民解放军第二军医大学 具有降血脂作用的3-取代氧基-3',4'-二甲氧基黄酮类化合物
JP5424296B2 (ja) * 2008-08-28 2014-02-26 静岡県公立大学法人 フラボン誘導体の製造方法およびシアル酸転移酵素阻害剤
JP2012525331A (ja) * 2009-04-27 2012-10-22 リメリック バイオファーマ, インコーポレイテッド 治療的処置のためのリン酸化ピロン類似体
JP2012044944A (ja) * 2010-08-27 2012-03-08 Railway Technical Research Institute トルエン検出方法
DE102011104441A1 (de) * 2011-06-16 2012-12-20 Fujitsu Technology Solutions Intellectual Property Gmbh Schaltnetzteil, Betriebsverfahren und Verwendung eines Schaltnetzteils in einem Computer
WO2013020184A1 (en) * 2011-08-11 2013-02-14 Neuprotect Pty Ltd Flavonoid compounds, and methods of use thereof
CN102631362B (zh) 2012-01-19 2013-04-24 中国人民解放军第二军医大学 射干异黄酮类化合物在制备预防和治疗紫外线致皮肤损伤药物中的应用
CN102617672B (zh) 2012-02-24 2014-03-12 大连大学 一种金花茶黄酮苷及其制备方法和用途
CN102697768A (zh) 2012-06-07 2012-10-03 中国人民解放军第二军医大学 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途
RU2679913C2 (ru) * 2012-10-02 2019-02-14 Сфинготек Гмбх Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции

Also Published As

Publication number Publication date
EP2906578A1 (en) 2015-08-19
ZA201502703B (en) 2016-11-30
AU2013330222B2 (en) 2016-05-12
RU2015117641A (ru) 2016-11-27
ES2730926T3 (es) 2019-11-13
KR102169002B1 (ko) 2020-10-23
US10316053B2 (en) 2019-06-11
EP2906578A4 (en) 2016-03-23
JP6567419B2 (ja) 2019-08-28
SG11201502758SA (en) 2015-05-28
EP2906578B8 (en) 2019-06-26
BR112015008156A2 (pt) 2017-07-04
CA2887488A1 (en) 2014-04-17
MX2015004578A (es) 2016-03-04
US20150259373A1 (en) 2015-09-17
MX368855B (es) 2019-10-18
AU2013330222A1 (en) 2015-05-21
CA2887488C (en) 2020-07-14
RU2647842C2 (ru) 2018-03-21
JP2018184414A (ja) 2018-11-22
NZ707087A (en) 2016-04-29
JP2015533128A (ja) 2015-11-19
KR20150096376A (ko) 2015-08-24
EP2906578B1 (en) 2019-05-08
CN107759553A (zh) 2018-03-06
CN104955831A (zh) 2015-09-30
WO2014056038A1 (en) 2014-04-17
DK2906578T3 (da) 2019-07-15

Similar Documents

Publication Publication Date Title
CR20140519A (es) Derivados de benzamida para la inhibición de la actividad de abl 1, abl 2 y bcr-abl 1
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
CR20150061A (es) Compuesto de pirazolopirimidinas
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
ECSP11011244A (es) Nuevos herbicidas.
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EA201590295A1 (ru) Atx-модулирующие агенты
MX373307B (es) Compuestos de biaril-amida como inhibidores de cinasa.
UY34591A (es) Compuestos de imidazopirrolidinona
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
BR112012033350A2 (pt) "composição e métodos para modular a via de sinalização de wnt"
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
MX2012012527A (es) Compuestos quimicos.
EA201290800A1 (ru) Гетероциклическое соединение
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
UY34523A (es) Derivados de betulina
ECSP14013251A (es) Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
CR20140322A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
ECSP13012366A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
DOP2013000051A (es) Compuestos heterociclico y sus usos